(68)Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.
Auteurs : Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P Année : 2022 Journal : J Nucl Med
The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.
Auteurs : Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC, Artigas C Année : 2022 Journal : Rev Esp Med Nucl Imagen Mol (Engl Ed)
Targeted radionuclide therapy: an emerging field in solid tumours.
Auteurs : Artigas C, Mileva M, Flamen P, Karfis I Année : 2021 Journal : Curr Opin Oncol
Oligometastatic Disease Detection with <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.
Auteurs : Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, Gil T, Peltier A, Van Gestel D, Flamen P Année : 2021 Journal : Cancers (Basel)
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
Auteurs : Bianchi L, Castellucci P, Farolfi A, Droghetti M, Artigas C, Leite J, Corona P, Shagera QA, Moreira R, González C, Queiroz M, de Galiza Barbosa F, Schiavina R, Deandreis D, Fanti S, Ceci F Année : 2021 Journal : Eur Urol Oncol